Physician profile
James Torain
NPI 1720641673
$1,639.78
in general payments reported to CMS, 2019-2025
16 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2024: $363 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391 · Education: $28.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.14 |
| Education | $28.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $226.21 | 2024-2025 | |
| Ardelyx, INC. | $168.22 | 2025 | Ibsrela, Xphozah 30 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.40 | 2022-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $146.30 | 2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $134.53 | 2024-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $123.61 | 2024-2025 | |
| Novo Nordisk INC | $121.82 | 2022 | |
| Mallinckrodt Hospital Products INC. | $106.98 | 2025 | Acthar |
| Travere Therapeutics, INC. | $85.25 | 2024-2025 | |
| Akebia Therapeutics INC | $82.94 | 2024-2025 | Vafseo |
| Fresenius USA Marketing, INC. | $76.26 | 2025 | Velphoro |
| Amgen INC. | $70.33 | 2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $66.55 | 2024-2025 | Farxiga |
| Ani Pharmaceuticals, INC. | $30.26 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $26.22 | 2024 | Lupkynis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $14.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Torain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.